Total mortality · people with primary hypertension
It is very uncertain whether combination therapy changes total mortality compared with monotherapy (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with primary hypertension
1 finding from 1 review
Cardiovascular events · people with primary hypertension
It is very uncertain whether combination therapy changes cardiovascular events compared with monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with primary hypertension
It is very uncertain whether combination therapy changes serious adverse events compared with monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with primary hypertension
It is very uncertain whether combination therapy changes withdrawals due to adverse effects compared with monotherapy (very low certainty).
1 finding from 1 review
Mortality ( · children aged from 29 days to 12 years with pneumonia
Chest physiotherapy may leads to lower mortality ( compared with no chest physiotherapy (low certainty).
1 finding from 1 review
Length of hospital stay · children aged from 29 days to 12 years with pneumonia
Chest physiotherapy showed no clear difference in duration of hospital stay (days) ( compared with no chest physiotherapy (low certainty).
1 finding from 1 review
Clinical resolution · children aged from 29 days to 12 years with pneumonia
Chest physiotherapy showed no clear difference in time to clinical resolution (all parameters) ( compared with no chest physiotherapy (low certainty).
1 finding from 1 review
Adverse events (number of events) ( · children aged from 29 days to 12 years with pneumonia
Chest physiotherapy showed no clear difference in adverse events (number of events) ( compared with no chest physiotherapy (low certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Reduction and pharmacotherapy may leads to higher main analysis (all pharmacotherapy): smoking cessation (≥ 6 month compared with reduction alone (low certainty).
1 finding from 1 review
FEV1 · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Z score FVC · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
HRCT score · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Weight (z score) · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Number of positive P aeruginosa isolates · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Number or proportion of hospitalisations · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Hospital costs · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
All‐cause mortality at 5 years · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes all‐cause mortality at 5 years compared with no chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found